U.S. markets closed

Epizyme, Inc. (EPZM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.4800+0.5260 (+55.14%)
At close: 04:00PM EDT
1.4800 0.00 (0.00%)
After hours: 07:59PM EDT

Epizyme, Inc.

400 Technology Square
4th Floor
Cambridge, MA 02139
United States
617 229 5872

Full Time Employees250

Key Executives

NameTitlePayExercisedYear Born
Mr. Grant C. BoglePres, CEO, Principal Financial Officer & Director923.32kN/A1958
Dr. Jeffery L. Kutok M.D., Ph.D.Chief Scientific Officer646.13kN/A1967
Dr. H. Robert HorvitzCo-Founder & Chairman of the Scientific Advisory BoardN/AN/AN/A
Dr. Yi ZhangScientific Co-Founder & Member of The Scientific Advisory BoardN/AN/AN/A
Mr. Jerald Korn J.D.Chief Operating OfficerN/AN/A1979
Mr. Joseph BeaulieuSr. VP, Head of Fin., Controller, Treasurer & Principal Accounting OfficerN/AN/A1981
Mr. Craig West CFAVP of Investor RelationsN/AN/AN/A
Mr. John F. WeidenbruchSr. VP, Gen. Counsel & Sec.N/AN/A1961
Ms. Tanja WeberChief Bus. OfficerN/AN/AN/A
Dr. Mark A. De Rosch Ph.D.Chief Regulatory OfficerN/AN/A1964
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Epizyme, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 5. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.